Peptides · Peptide comparison
Leuprolide vs Triptorelin
A powerful GnRH agonist that helps manage hormone-sensitive conditions by controlling hormone production.
GnRH agonist that helps manage prostate cancer, endometriosis, and early puberty by controlling sex hormones
- Hormone Support
- Hormone Support
At a glance
Quick comparison
Efficacy
Benefit ratings
Cancer Management
Endometriosis & Fibroid Relief
Hormone Control
Hormone Regulation
Endometriosis Relief
Technical data
Compound specifications
Leuprolide
- Molecular formula
- C59H84N16O12
- Molecular weight
- 1209.4 g/mol
- Half-life
- Approximately 2-6 hours (varies by route of administration)
- Bioavailability
- ~95% (subcutaneous injection)
- CAS number
- 74381-53-6
Triptorelin
- Molecular formula
- C64H82N18O13
- Molecular weight
- 1311.4 g/mol
- Half-life
- 2-3 hours (free peptide); 2-4 weeks (depot pamoate formulations)
- Bioavailability
- ~100% (intramuscular/subcutaneous injection)
- CAS number
- 57773-63-4
Protocols
Dosing compared
Leuprolide
Subcutaneous
- 1 mgOnce daily · OngoingThe original daily form is a 1 mg shot under the skin each day for advanced prostate cancer. It works but needs a shot every day, so most people now use the longer-acting depot instead [4].
Intramuscular
- 7.5 mgEvery month · OngoingThe 1-month depot is a single 7.5 mg shot into the muscle every 4 weeks. One injection replaces a month of daily shots [5].
- 22.5 mgEvery 3 months · OngoingThe 3-month depot is a 22.5 mg muscle injection given once every 3 months, so fewer office visits [5].
- 30-45 mgEvery 4-6 months · OngoingThe longest-acting depots: 30 mg every 4 months, or 45 mg every 6 months. These need only 2-3 injections per year [5].
Triptorelin
Intramuscular injection
- 3.75 mgOnce every 4 weeks · Ongoing while indicatedFDA-labeled 1-month depot (Trelstar) for advanced prostate cancer; single IM injection into either buttock [5].
- 11.25 mgOnce every 12 weeks · Ongoing while indicatedFDA-labeled 3-month depot (Trelstar). Strengths are not additive; chosen by desired interval [5].
- 22.5 mgOnce every 24 weeks · Ongoing while indicatedFDA-labeled 6-month depot (Trelstar for prostate cancer; Triptodur 22.5 mg for central precocious puberty, ages 2+) [5][6].
Applications
Best suited for
Leuprolide
- Managing advanced or metastatic prostate cancer
- Leuprolide is particularly well-suited for individuals focused on managing advanced or metastatic prostate cancer. Research and clinical experience suggest meaningful benefits in this area when used as part of a comprehensive treatment approach [1][5].
- Controlling severe endometriosis pain
- Leuprolide is particularly well-suited for individuals focused on controlling severe endometriosis pain. Research and clinical experience suggest meaningful benefits in this area when used as part of a comprehensive treatment approach [1].
- Treating symptomatic uterine fibroids
- Leuprolide is particularly well-suited for individuals focused on treating symptomatic uterine fibroids. Research and clinical experience suggest meaningful benefits in this area when used as part of a comprehensive treatment approach [1].
- Delaying early puberty in children
- Leuprolide is particularly well-suited for individuals focused on delaying early puberty in children. Research and clinical experience suggest meaningful benefits in this area when used as part of a comprehensive treatment approach [1].
Triptorelin
- Managing advanced prostate cancer when combined with other treatments
- Triptorelin is particularly well-suited for individuals focused on managing advanced prostate cancer when combined with other treatments. Research and clinical experience suggest meaningful benefits in this area when used as part of a comprehensive treatment approach.
- Relieving severe endometriosis pain and symptoms
- Triptorelin is particularly well-suited for individuals focused on relieving severe endometriosis pain and symptoms. Research and clinical experience suggest meaningful benefits in this area when used as part of a comprehensive treatment approach.
- Delaying puberty development in children with early sexual maturation
- Triptorelin is particularly well-suited for individuals focused on delaying puberty development in children with early sexual maturation. Research and clinical experience suggest meaningful benefits in this area when used as part of a comprehensive treatment approach.
Safety profile
Side effects
Leuprolide
Common
- Hot flashes (very common in men)
- Decreased libido and erectile dysfunction
- Injection site pain or swelling
- Nausea
- Fatigue
- Mood changes or depression
- Joint or muscle pain
- Headaches
- Dizziness
- Thinning hair
- Decreased bone density (osteoporosis with long-term use)
- QT prolongation (rare but serious cardiac effect)
- Tumor flare (temporary worsening of cancer symptoms in first weeks)
- Severe allergic reactions
- Spinal cord compression risk in men with metastatic disease
Serious
- Severe allergic reaction
Triptorelin
No side effects recorded.
Research status
Safety & evidence
Leuprolide
- Evidence level
- Strong human trials (Phase 3 or FDA approved)
- FDA status
- FDA approved for this use
- Safety overview
- Leuprolide (Lupron) is an FDA-approved GnRH agonist with 35+ years of clinical safety data involving millions of patients in oncology and endocrinology. [1] The critical safety issue is the initial 5-7 day flare effect—temporary surge in FSH/LH causing symptom worsening before hormone suppression begins—particularly dangerous for prostate cancer patients (flare can cause urinary obstruction or spinal cord compression). [5] Bone density loss is a dose-dependent long-term risk in both men and women requiring monitoring. [1][5] Injection site reactions, hot flushes, and initial hypogonadal symptoms are expected and typically transient. [5]
Contraindications
- Pregnancy (may cause fetal harm) [6]
- Undiagnosed vaginal bleeding [6]
- Allergy to GnRH agonists or components [5][6]
Triptorelin
- Evidence level
- Strong human trials (Phase 3 or FDA approved)
- FDA status
- FDA approved for this use
- Safety overview
- Triptorelin (GnRH agonist) has extensive FDA-approved safety data spanning decades for prostate cancer, endometriosis, and precocious puberty indications. Initial testosterone surge upon initiation ("flare reaction") can worsen prostate cancer or spinal cord compression symptoms, requiring careful patient monitoring in first 1-2 weeks and use of androgen antagonists in high-risk patients. Hypogonadal effects including hot flashes, sexual dysfunction, and bone loss develop predictably with chronic GnRH suppression; bone density monitoring is recommended in patients on therapy >6 months.
Contraindications
- Pregnancy (can affect fetal development)
- Undiagnosed vaginal bleeding
- Known hypersensitivity to GnRH agonists
- Severe untreated depression
- Active spinal cord compression in prostate cancer (requires urgent decompression)
Decision guide
Which is right for you?
Leuprolide
Choose Leuprolide if…
- Managing advanced or metastatic prostate cancer
- Controlling severe endometriosis pain
- Treating symptomatic uterine fibroids
- Delaying early puberty in children
Triptorelin
Choose Triptorelin if…
- Managing advanced prostate cancer when combined with other treatments
- Relieving severe endometriosis pain and symptoms
- Delaying puberty development in children with early sexual maturation